MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - May 30, 2012) -
MorphoSys AG /
MorphoSys Announces New Management Appointments
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today
that it
has strengthened its management in two positions. Charlotte Lohmann
joins the
Company as General Counsel, and Martin Clark as Head of Central
Purchasing &
Logistics.
Charlotte Lohmann joins MorphoSys after eleven years at Wilex AG where
she was
most recently Senior Vice President Legal Affairs & Human Resources.
Prior to
her position at Wilex, she practiced as a lawyer at the law firm KPMG
Treuhand &
Goerdeler GmbH in Munich. She started her career in the tax and law
department
of the auditing company KPMG Deutsche Treuhand-Gesellschaft AG in the
Munich
office. Mrs. Lohmann received her degree in law from the University of
Munich
and is a licensed attorney.
Martin Clark joins MorphoSys from Sandoz Biopharmaceuticalswhere he
managed the
delivery of projects via third party contract research organizations as
Head of
Clinical Operations and Third Party Management. He has over 30 years
experience
in the pharmaceutical industry filling both scientific and management
positions
with Basilea, Serono, Merck-Serono, Novartis and Pfizer.
"We are very pleased to welcome outstanding individuals for two
important
positions within the MorphoSys Group," explained Dr. Simon Moroney,
Chief
Executive Officer of MorphoSys AG. "These additions will further
strengthen and
complement our existing management team, and will help us to continue to
build
MorphoSys as a leading biopharmaceutical company."
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology
in
the pharmaceutical industry. By successfully applying this and other
patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
The
Company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
applications.
Together with its pharmaceutical partners, MorphoSys has built a
therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment
of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow.
MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
updates
about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®,
Ylanthia®, CysDisplay®,
RapMAT® and arYla® are registered trademarks of MorphoSys AG.
This communication contains certain forward-looking statements
concerning the
MorphoSys group of companies. The forward-looking statements contained
herein
represent the judgment of MorphoSys as of the date of this release and
involve
risks and uncertainties. Should actual conditions differ from the
Company's
assumptions, actual results and actions may differ from those
anticipated.
MorphoSys does not intend to update any of these forward-looking
statements as
far as the wording of the relevant press release is concerned.
Media Release (PDF):
http://hugin.info/130295/R/1615757/515147.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1615757]